期刊文献+

化学发光免疫法检测BNP的分析测量范围和临床可报告范围研究 被引量:6

Research on the Analytical Measuring Range and Clinical Reportable Range of Chemiluminscence Immunoassay in Detection of BNP
暂未订购
导出
摘要 目的 研究化学发光免疫法检测B型钠尿肽(BNP)的分析测量范围(AMR)和临床可报告范围(CRR).方法 参照美国临床和实验室标准化研究院(CLSI)发布的EP6-A文件要求制备实验样品,每个样品在西门子ADVIA Centaur化学发光免疫分析系统上重复测定2次,利用多项式回归法确定BNP的分析测量范围;通过稀释回收试验确定最大稀释度,结合功能灵敏度和分析测量范围上限确定临床可报告范围.结果 ADVIA Centaur化学发光免疫分析系统的分析测量范围为2.0~5 094 pg/ml,临床可报告范围为2.5~10 188 pg/ml.结论 厂商声明的ADVIA Centaur化学发光免疫系统检测BNP的分析测量范围得到验证确认,但对于超过分析测量范围的高值标本建议用生理盐水做1∶2稀释. Objective To study the analytical measuring range (AMR) and clinical reportable range(CRR) of ehemiluminseence immunoassay in detection of B-type Natriuretie Peptide(BNP). Methods Referring to NCCLS EP6-A evaluation protocols,performed the experiments on analytical measurement rang and maximal dilution rate using ADVIA Centaur chemiluminescence immunoassay system. The AMR was analysed using polynomial regression,and the maximal dilution rate was determined by diluting-recovery tests,by which the CRR could be found. Results The analytical measurement rang of BNP was 2.0-5 094 pg/ml. And the clinical reportable range was 2.5-10 188 pg/ml. Conclusion The AMR and CRR of chemiluminescence immunoassay in detection of BNP met clinical requirements ,and the recommended dilution was 1 : 2 with saline.
出处 《现代检验医学杂志》 CAS 2011年第2期40-42,45,共4页 Journal of Modern Laboratory Medicine
基金 广东省医学科研基金课题(A2009763),中山市科技局资助课题(20091A038).
关键词 B型钠尿肽 方法学评价 化学发光免疫测定法 分析测量范围 临床可报告范围 B-type natriuretic peptide(BNP) methodology evaluation chemiluminescence immunoassay analytical measurement rang clinical reportable range
  • 相关文献

参考文献8

  • 1张秀明,庄俊华,郑松柏,徐建华,马骥,孙蕾,林莲英,柯培锋,梁伟雄.临床化学发光免疫法检测AFP的分析性能验证与实验方法[J].中华检验医学杂志,2007,30(11):1293-1297. 被引量:64
  • 2潘柏申,杨振华,吴健民.冠状动脉疾病和心力衰竭时心脏标志物临床检测应用建议[J].中华检验医学杂志,2006,29(9):774-778. 被引量:73
  • 3Clinical and Laboratory Standards Institute.User de-monstration of performance for precision and accuracy[S].Approved Guideline EP-6A,CLSI:2004.
  • 4郑松柏,张秀明,庄俊华,林莲英,徐建华,王建兵,马骥,柯培锋.化学发光免疫法检测甲胎蛋白临床可报告范围的建立[J].中国现代医学杂志,2008,18(14):2069-2071. 被引量:12
  • 5杨有业,张秀明.临床检验方法学评价[M].北京:人民卫生出版社,2008:118-127.
  • 6Wians FH Jr,Wilson BA,Grant A,et al.Evaluation of the analytical performancecharacteristics of the Bayer ACS:180? B-type natriuretic peptide (BNP) assay[J].Clin Chim Acta,2005,353(1-2):147-155.
  • 7Alibay Y,Schmitt C,Beauchet A,et al.Non-radioimmunometric NT-ProBNP and BNP assays:impact of diluent,age,gender,BMI[J].Ann Biol Clin,2005,63(1):43-49.
  • 8Prontera C,Zaninotto M,Giovannini S,et al.Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP(NT-proBNP) immunoassays:the CardioOrmocheck study[J].Clin Chem Lab Med,2009,47(6):762-768.

二级参考文献47

  • 1秦晓光.“检查结果互认”和质量管理[J].中华检验医学杂志,2007,30(2):132-135. 被引量:45
  • 2李金明,申子瑜.正确认识临床实验室认可与提高检验质量之间的关系[J].中华检验医学杂志,2007,30(2):136-139. 被引量:38
  • 3毕波,吕元.定量检测方法学性能验证的系统设计[J].中华检验医学杂志,2007,30(2):143-145. 被引量:153
  • 4魏吴 丛玉隆.医学实验室质量管理与认可指南[M].北京:中国计量出版社,2004.72-75.
  • 5Pearson TA, Mensah GA, Hong Y, et al. CDC/AHA Workshop on markers of inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice : Overview. Circulation, 2004,110 : e543-544.
  • 6Myers GL,Rifai N,Tracy RP,et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease : Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation ,200d, 110 :e545-549.
  • 7Smith SC Jr, Anderson JL, Cannon RO 3rd, et al. CDC/AHA Workshop on Markers of inflammation and Cardiovascular Disease:Application to Clinical And Public Health Practice: report from the clinical practice discussion group. Circulation,2004, 110 : e550-553.
  • 8Fortmann SP, Ford E, Criqui MH, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease : Application to Clinical and Public Health Practice: report from the population science discussion group. Circulation,2004, 110 : e554-559.
  • 9Biasucci LM, CDC, AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease : Application to Clinical and Public Health practice: clinical use of inflammatory markers in Patients with cardiovascular diseases : a background paper.Circulation ,2004, 110 :e560-567.
  • 10Wilson PW, CDC, AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease:Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. Circulation,2004,110:e568-571.

共引文献295

同被引文献43

  • 1史晓敏,徐国宾,夏铁安.B型尿钠肽的生物学特性及其测定的临床应用[J].临床检验杂志,2005,23(1):67-70. 被引量:47
  • 2周琦,李少男,李小鹏,王薇,王治国.利用美国国家临床实验室标准化委员会EP6-A指南判定线性[J].中华检验医学杂志,2006,29(1):85-86. 被引量:31
  • 3毕波,吕元.定量检测方法学性能验证的系统设计[J].中华检验医学杂志,2007,30(2):143-145. 被引量:153
  • 4吴凤丽,马晓光,孙玉珍,冯静文,张丽霞.血清CK-MB活力假性增高原因分析及临床意义[J].中国实验诊断学,2007,11(8):1041-1043. 被引量:34
  • 5NCCLS. User demonstration of performance for pre- cision and accureaey, Approved guideline[S]. Wayne, PA : NCCLS Document EP15-A, 2001.
  • 6Yco KT,Wu AH, Apple FS, et al. Multicenter evalua- tion of the Roche NT-proBNP assay and comparison to the biosite triage BNP assay[J]. Clinica Chimica Acta, 2003,338 (1/2) : 107-115.
  • 7Prontera C, Zaninotto M, Giovannini S, et al. Profi- ciency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassay: the CardioOrmo- check study[J]. Clin Chem Lab Med, 2009,47 (7) : 762-768.
  • 8Lippi G,Fortunato A,Salvagno GL,et al. Influence of sample matrix and storage on BNP measurement on the Bayer Advia Centaur[J]. J Clin Lab Anal, 2007, 21(5) :293-297.
  • 9Lippl G, Salvagno GL, Montagnana M, et al. Measu- rement of Elecsys NT-proBNP in serum, K2 EDTA and heparin plasma [J]. Cliniea Biochem, 2007,40 (9/ 10) :747-748.
  • 10Abelardo MR, Richards AM,Jone CB, et al. Biology of the natriuretie peptides[J]. Am J Cardiol,2008,101 (3A):3-8.

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部